The results of the trial also suggested that the combined theraphy also helps in the reduction of the risk of cancer progression by 57% versus exemestane alone in patients with advanced breast cancer.
Data from Bolero-2 support worldwide regulatory submissions, which are planned by the end of 2011.
Bolero-2 study aimed to evaluate the safety and efficacy of everolimus in conjunction with exemestane versus exemestane alone in postmenopausal women with ER+HER2- advanced breast cancer who recurred or progressed while on or following previous treatment with hormonal therapies, letrozole or anastrozole.